SARS-CoV-2-IN-34

SARS-CoV-2-IN-34

• CAS Number: 3029103-37-2
• UNSPSC Description: SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection[1].
• Target Antigen: SARS-CoV
• Type: Peptides
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/sars-cov-2-in-34.html
• Solubility: 10 mM in DMSO
• Smiles: CC(C[C@H]1CN(CC(N[C@H](CN(CC(N[C@H](CN(C(CCSCC2=CC=C(C(N[C@H](CN(CC(N1)=O)C(CCCN)=O)CC3=CC=CC=C3)=O)C=C2)=O)CC(NCCC(N[C@H](CN(C(CCC(O)=O)=O)CC(N)=O)CCC(O)=O)=O)=O)CC4=CC=CC=C4)=O)C(CC5=CC=C6C=CC=CC6=C5)=O)CC7=CC=CC=C7)=O)C(CCC8CCCCC8)=O)C
• Molecular Weight: 1683.06
• References & Citations: [1]Xue S, et al. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein. Cell Discov. 2022 Sep 8;8(1):88.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported